Loblaw, a major grocery retailer, saw an increase in profits during the second quarter, driven by strong sales at its discount chains No Frills and Maxi. The company also experienced robust growth in its pharmacy unit, attributed to the popularity of generic GLP-1 weight loss medications.
Based in Brampton, Ontario, Loblaw released its financial results for the quarter ending June 20, reporting revenue exceeding $15.3 billion, a four percent increase from the previous quarter. The profit available to common shareholders rose by five percent to $751 million.
The company noted a 1.6 percent increase in same-store sales for its retail food business, with even stronger growth of 4.6 percent in its drug retail unit, driven by a 7.5 percent rise in pharmacy and health-care services sales.
Chief Financial Officer Richard Dufresne highlighted the impact of generic GLP-1 drugs on pharmacy performance, noting early positive indicators of lower generic drug pricing being offset by higher volumes, leading to expected revenue and profit increases.
The GLP-1 drug category, including brands like Ozemic and Wegovy, has seen a 40 percent sales uptick year-to-date, following a trend observed in the previous quarter.
CEO Per Bank mentioned on an analyst call that consumers are increasingly opting for frozen vegetables over fresh produce due to inflation, with significant price increases in fresh items like tomatoes. Loblaw’s No Frills and Maxi stores have seen growth in frozen vegetable sales as customers seek to manage their grocery costs.
Despite food price inflation, Loblaw remains competitive in the market, gaining market share in hard discount and outperforming peers in conventional retail. The company’s internal food inflation metric remains lower than the national grocery CPI.
Statistics Canada reported a decline in the headline inflation rate to 2.8 percent in June, with grocery price increases moderating to 3.9 percent from 4.3 percent in May. Loblaw’s stock traded flat on Thursday, showing a six percent year-to-date increase.
Overall, Loblaw’s strategic focus on value offerings and pharmacy services has contributed to its financial success in the second quarter.